Most foreign brands obsess over whether a product can physically clear Chinese customs, then assume the hard part is over. It is not. The moment you describe that product to a Chinese shopper – on a listing page, in a live stream, on a package insert, or in a paid ad – you are making claims, and every claim is a compliance obligation. China runs one of the strictest advertising and product-claim regimes in the world, and cross-border sellers are squarely inside it. A claim you could make legally in your home market can be an illegal absolute term, an unsubstantiated efficacy promise, or a misleading comparison in China, exposing you to fines, listing takedowns, refunds, and after-sales disputes. This guide walks cross-border brands through product claim substantiation and compliance: what counts as a claim, which claims are high-risk, what evidence the regulator and platforms expect, and how false claims come back to haunt your after-sales operation.
1. What actually counts as a “claim”
A claim is any statement that conveys a specific attribute, effect, or benefit of a product. It is not limited to bold marketing slogans. Product names, function descriptions, ingredient callouts, “before and after” visuals, star ratings you surface, and even the way you translate a foreign label can all be read as claims. The trap for foreign brands is assuming that only overt advertising is regulated. In China, a product detail page is advertising, a live-stream demonstration is advertising, and a package insert is advertising. If the text or image suggests a result, a function, a safety level, or a comparative advantage, you need a basis for saying it. The first discipline is therefore a claim inventory: list every statement you make about the product across every channel, then ask for each one – what is our evidence?
The home-market translation trap
Brands frequently lift copy from their domestic sites and translate it directly. Words like “best”, “clinically proven”, “doctor recommended”, “number one”, or “guaranteed results” may be permissible where you are based but are precisely the terms Chinese advertising law restricts or bans. Translation is not a defense; the Chinese-language version is what is enforced. Treat every imported phrase as a fresh compliance question, not a settled one.
Implied claims count too
You do not have to say “cures” to imply a therapeutic effect. Showing a person with clear skin next to a serum, or a weight figure dropping beside a tea, communicates a result. Regulators and platforms are trained to read implication, so your substantiation file must cover the claim you meant and the claim a reasonable shopper would take away.
2. High-risk claim categories
Some categories of claims attract disproportionate scrutiny because they touch health, safety, or consumer trust. Knowing them lets you route the risky ones to legal review before they reach a listing. The consistently high-risk groups are efficacy and therapeutic claims on non-drug products, absolute and superlative terms, comparative claims against named competitors, before-and-after demonstrations, and “natural”, “organic”, “green”, or “free-from” assurances that a shopper reads as a safety or purity promise.
Efficacy and therapeutic claims
Claims that a cosmetic, food, supplement, or device prevents, treats, or cures a condition are the single largest source of penalties. A skincare product is not a drug; describing it as able to “repair” damaged tissue or “treat” acne edges into medical claims that require drug registration you do not hold. Keep benefit language within the approved function scope for the product’s category.
Absolute and superlative terms
China’s Advertising Law prohibits terms that denote a supreme level – expressions equivalent to “national level”, “highest grade”, “best”, “number one”, or “most”. These are caught automatically by platform ad filters and by regulator sweeps. Replace them with measurable, defensible language tied to a specific test or survey.
Comparative and “free-from” claims
Comparing yourself to a named rival invites defamation and unfair-competition exposure unless the comparison is verifiable and fair. “Free from” claims (no additives, no sugar, non-toxic) must be literally true across the full formulation and supply chain, or they become misleading.
3. The evidence standard: what SAMR and platforms expect
The core rule is simple to state and hard to live by: you must hold objective, verifiable evidence that reasonably supports each claim at the moment you make it. The evidence hierarchy runs from weakest to strongest as: internal assertion, a single supplier statement, third-party test reports, controlled studies, and recognized certifications. For efficacy or safety claims, a single self-authored note will not survive scrutiny; you need a test report from an accredited laboratory or a study with a defined methodology. Keep the original reports, not just summaries, because both the platform and the market regulator (SAMR) can demand the underlying documents.
Accreditation and recognition
Evidence carries weight when it comes from a laboratory accredited under ISO/IEC 17025 or recognized through mutual arrangements such as CNAS, ILAC, or bodies like SGS, TUV, BV, and Intertek. A test run on your own bench is useful internally but is rarely sufficient as public substantiation.
Sample retention and version control
Claims are assessed against the exact batch a complainant bought. Retain a retained sample and the corresponding test for each material change, and version-control your claim dossier so you can prove the evidence matched the product on sale at the time of the complaint.
4. China’s Advertising Law and the absolute-terms ban
The Advertising Law of the People’s Republic of China, together with sector rules from SAMR, sets the baseline. Beyond the ban on supreme-level terms, it restricts health and safety claims, requires that recommendations by endorsers reflect actual use, and imposes strict liability on advertisers for false or misleading content. Penalties scale with the ad spend and the harm, and in serious cases reach multiple of the advertising cost plus order suspension. For cross-border goods sold through the 1210 bonded model, the same rules apply to the in-China listing even though the product entered under a different customs path.
Endorser and live-stream liability
A key change many foreign brands miss: the host or influencer who recommends the product shares liability for false claims made during a live stream. If your local agency runs a Douyin or RED broadcast using your approved script, a banned term spoken on air is still your claim. Lock the script and train the presenter.
5. Category-specific rules you cannot ignore
General advertising law is only the floor. Each product category layers its own claim regime. Cosmetics are governed by NMPA rules requiring that efficacy claims match a registered function and, for certain claims, be supported by human efficacy testing. Health foods and foods follow separate labeling and function-claim limits and may not imply disease prevention or treatment. Medical devices may state only the approved intended use. Ordinary consumer goods still must be truthful and not imply safety or performance they lack. Mapping your SKU to its category rule set is step one of any claim review.
Cosmetics efficacy claims
Under NMPA’s cosmetic claim rules, you may only claim functions you have evidenced, and several high-impact claims (such as sunscreen, whitening, or anti-acne) require specific testing dossiers. Imported cosmetics must align the Chinese claim set with the home registration and not promise more than the dossier supports.
Foods and supplements
Food and supplement claims are tightly capped: you may not claim disease prevention or treatment, and any function claim must sit within the permitted list for the product type. “Immune support” wording that implies therapeutic benefit is a frequent takedown trigger.
6. Platform ad review and takedown mechanics
Even before a regulator acts, the platforms police claims. Tmall Global, JD Worldwide, RED, and Douyin each run pre-publication ad review and continuous post-publication scanning. A flagged claim can trigger a soft warning, a listing edit demand, a takedown, or a store-level penalty that freezes your ability to sell during a peak. Because cross-border stores are reviewed in Chinese, an English back-end field that leaks into the front end is treated as a live claim. Build your claim review into the listing launch, not after a penalty lands.
Speed of enforcement
Platform scanning is automated and constant. A prohibited absolute term can be caught within hours of going live, often before you have sold a unit – but also after thousands, which is when the after-sales exposure compounds. The cheap time to fix a claim is before publication.
7. Documentation to keep: the claim dossier
Substantiation is only as good as the file you can produce under pressure. Maintain a claim dossier per SKU that records each claim, its permitted category basis, the exact evidence (with issuing lab, date, and method), the retained sample link, and the approval sign-off. Keep it in Chinese as well as the source language so local reviewers and regulators are not waiting on translation. Version it alongside product reformulation so old evidence never backs a new formula.
Translation as a controlled step
The Chinese claim is the legally binding one. Treat translation as a controlled, reviewed step with a record, not a casual copy-paste, so you can show the claim you published is the claim you intended and evidenced.
8. After-sales fallout: how false claims come back to you
This is where claim compliance meets the after-sales desk, and why the evening team cares. A false or unsubstantiated claim does not stay a marketing problem; it becomes a returns, refund, and dispute problem. Buyers who did not get the promised result invoke the claim as the basis for a return or a refund request, often within the seven-day unconditional return window or as a quality dispute. Platforms side with the buyer when the claim is unsubstantiated, which means you absorb the refund, the return shipping, and the rating hit. Worse, a pattern of claim disputes feeds the platform’s risk model and can throttle your store. Documented substantiation is your shield: when a dispute arises, a clean evidence file lets you defend the claim or, failing that, pivot fast to a compliant rewrite before the dispute escalates.
Disputes, liability, and refunds
Where a claim crosses into a safety or health deception, consumer-protection liability and even product-liability exposure follow, independent of the ad fine. The after-sales cost – refunds, returns, reputational damage, and the time your team spends firefighting – routinely exceeds the original ad savings from cutting the compliance corner.
9. A claim-compliance checklist and common mistakes
Before any listing or live stream goes live, verify: a complete claim inventory exists for the SKU; each claim maps to its category’s permitted basis; objective evidence (accredited test or study) is on file and version-matched to the batch; no supreme-level or banned absolute terms appear in Chinese; no therapeutic language sits on a non-drug product; comparative and free-from claims are verifiable; the Chinese translation was reviewed as a controlled step; platform ad-review rules for the specific channel were checked; and the claim dossier is accessible to local reviewers. The common mistakes are lifting home-market copy without review, trusting a supplier’s claim without independent evidence, assuming live-stream scripts are someone else’s liability, and treating substantiation as paperwork rather than the defense that protects your after-sales line.
Product claim substantiation is not red tape slowing down your launch; it is the quiet infrastructure that keeps a cross-border brand out of fines, takedowns, and refund spirals. Anchor the practice on three moves: inventory every claim, hold accredited evidence matched to the exact batch on sale, and review the Chinese-language wording as the legally binding version. Do those and a bold claim becomes a competitive asset; skip them and the same claim becomes the reason a customer returns the product, the platform freezes the listing, and the regulator sends the notice.